Oncology

For information on the following Clinical Trials, please contact the
Hematology, Oncology and Stem Cell Transplantation Department
at 773-880-4562 during 8:30 AM to 5:00 PM Central Standard Time.

 

  Acute Lymphoblastic Leukemia (ALL): 

Investigator 
AALL0433 Intensive Treatment for Intermediate-risk Relapse of Childhood B-Precursor acute Lymphoblastic Leukemia (ALL); A Randomized Trial of Vincristine Strategies   Elaine Morgan, MD 
AALL0434 Intensified Methotrexate, Nelarabine (Compound 506u78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia   Elaine Morgan, MD 
AALL05B1  A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Elaine Morgan, MD
AALL0622  Intensified Tyrosine Kinase Inhibitor Therapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Elaine Morgan, MD
AALL0631 A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)

Elaine Morgan, MD
AALL07P1 A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND# 58,443) in Combination with Intensive Re Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)  

Elaine Morgan, MD
AALL07P2 Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase®; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children with Acute Lymphoblastic Leukemia (ALL)  Nobuko Hijiya, MD
AALL0932        Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) Elaine Morgan, MD
CA180226 Phase II Study of Dasatinib Therapy for CML or PH+ Nobuko Hijiya, MD
CAMN107A21 A Mulit-Center, Open-Label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients with Gleeved (Imatinib)-Resistant/Intolerant Ph+ CML Chronic Phase (CP) or Accelerated Phase (AP) or With Refractory/Relapsed Ph+ ALL Nobuko Hijiya, MD
CPKC412A21 A Phase I/II, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Twice Daily Oral Midostaurin and to Evaluate the Preliminary Clinical and Pharmacodynamic Response in Pediatric Patients with Relapse Nobuko Hijiya, MD
T2008-002 A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse) A Joint Study of TACL and POETIC Nobuko Hijiya, MD
T2009-007 A Phase I Study Evaluation of the Safety, Tolerability and Biology Activity of EZN-3042, A Survivin mRNA Anatagonist, Administered with Re-Induction of Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL) [IND 108753] Nobuko Hijiya, MD
Extra BM Extra Bone Marrow Collection David Walterhouse, MD
     
  Acute Myeloid Leukemia (AML):  Investigator 
AAML06P1 A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young Patients with Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia Nobuko Hijiya, MD
AAML0631 Risk Adapted Treatment of Newly Diagnosed Childhood acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during Consolidation Nobuko Hijiya, MD
AAML08B1 Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS) Elaine Morgan, MD
AAML1031     A Phase III Randomized Trial for Patients with de novo AML Using Bortezomib (IND# 58443, NSC #681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD Nobuko Hijiya, MD
ACCL0933 A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) David Walterhouse, MD
     
  Developmental Therapeutics:  Investigator 
ADVL06B1     A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer Stewart Goldman, MD
ADVL0813 A Phase Istudy of IMC-A12 in Combination with CCI-779 (Temsirolimus) n Pediatric Patients with Recurrent or Refractory Solid Tumors Stewart Goldman, MD
ADVL0816 A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with Vincristine/Doxorubicin/Dexrazoxane, in Children with Relapsed/Refractory Solid Tumors or Leukemia Stewart Goldman, MD
ADVL0821     Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody IND# 100947, NSC# 742460) in Children with Relapsed/Refractory Solid Tumors  Stewart Goldman, MD
ADVL0911 A Phase I Dose Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, Ewing Family of Tumors and Rare Tumors with Neuroendocrine Features Stewart Goldman, MD
ADVL0912 A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed / Refractory Solid Tumors and Anaplastic Large Cell Lymphoma Stewart Goldman, MD
ADVL0916 A Phase I Study of Vorinostat and Bortezomib in Children with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphomas. Stewart Goldman, MD
ADVL0918     A Phase I Study of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors  Stewart Goldman, MD
ADVL0921 A Phase II Study of MLN8237 (IND#102984), A Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias   Stewart Goldman, MD
ADVL1011  A Phase I Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, Rare Tumors with Neuroendocrine  Features  Stewart Goldman, MD
ADVL1013 A Phase 1 Study of MK-2206, an AKT Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemia  Stewart Goldman, MD
ADVL1014 A Phase 1 Dose Escalation Study of REOLYSIN, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors Stewart Goldman, MD
ADVL1112 A Phase 1 Study of Imetelstat, A Telomerase Inhibitor in Children with Refractory Solid Tumors and Lymphomas Stewart Goldman, MD
ACNS0927 ACNS0927, A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)  Stewart Goldman, MD
     
  Ewings Sarcoma:  Investigator 
AEWS07B1 A COG Study for Collecting and Banking Ewing Sarcoma Specimens David Walterhouse, MD
AEWS1031    A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma David Walterhouse, MD
     
  Hepatoblastoma (HEP):   Investigator 
AHEP0731 Treatment of Children with All Stages of Hepatoblastoma:A Groupwide Phase III Study Yasmin Gosiengfiao, MD
     
  Hodgkins (HOD):   Investigator 
AHOD04B1 Hodgkin Disease Banking Study Yasmin Gosiengfiao, MD
     
  Late Effects:   Investigator 
ALTE03N1 Key Adverse Events after Childhood Cancer  Reggie Duerst, MD
ALTE05N1 Umbrella Long-Term Follw-up Protocol Jennifer Reichek, MD
ALTE07C1 Neuropsychological Testing Stewart Goldman, MD
     
  LCH/HLH:   Investigator 
HLH-2004 Hemophagocytic Lymphohistiocytosis: Treatment Protocol of the Second International Study, HLH-2004 Elaine Morgan, MD
     
  Miscellaneous:   Investigator 
Continued Participation Continued Participation in COG Research David Walterhouse, MD
CMH 10S01 Cardiac-Sparing Whole Lung IMRT in Children and Young Adults with Lung Metastases: A Feasibility Study David Walterhouse, MD
ACCL0935 Prevention of Cancer/Treatmetn-Related Weight Loss in Children at High Nutritional Risk Stewart Goldman, MD
ACCL1032 A Randomized Controlled Trial of Acupressure to Control Chemotherapy-induced Nausea (CIN) in Children Receiving Cisplatin Jennifer Reichek, MD
ANHL0221 A Phase II Study of the Combination of Cyclophosphamide, Predisone and Rituximab (CPR) in Children, Adolescents and Young Adults with CD20 Positive Post-Transplant Lymphoproliferative Disease (PTLD) following Solid Organ Transplantation (SOT) Elaine Morgan, MD
ACCRN07 Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) David Walterhouse, MD
AYA Q Understanding Adolescent and Young Adult Experiences of Childhood Cancer Jennifer Reichek, MD
ORACLE Ovarian Reserve After Cancer: Longitudinal Effects (ORACLE). A Multicenter Prospective Cohort Study by the Oncofertility Consortium Yasmin Gosiengfiao, MD
Ovarian Cryopreservation Ovarian Tissue Freezing Prior to Chemotherapy or Radiation Therapy Yasmin Gosiengfiao, MD
VARIZIG Varicella Zoster Immune Globulin (Human) (VariZIGTM) Expanded Access Protocol VZ-009 Elaine Morgan, MD
     
  Neuroblastoma (NBL):   Investigator 

ANBL0032    
   

Phase III Randomized Study of Chimeric Antibody 14.18 in High Risk NBL following Myeloablative Therapy and Autologous Stem Cell Rescue

 

  Joanna Weinstein, MD
 
ANBL00B1 Neuroblastoma Biology Studies Joanna Weinstein, MD
ANBL00P3 Use of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus Joanna Weinstein, MD
ANBL0532 Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma Joanna Weinstein, MD
     
  Osteosarcoma (OST):   Investigator 
AOST06B1 A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens David Walterhouse, MD
     
  Rare Tumors (RAR):   Investigator 
ABTR01B1   
 		 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors David Walterhouse, MD
 
ARAR0331 Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy  David Walterhouse, MD
ARAR0332 Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy   Yasmin Gosiengfiao, MD
     
  Renal (REN):   Investigator 
9442 National Wilms' Tumor Late Effects Study  Morris Kletzel, MD
AREN0321 Treatment of High Risk Renal Tumor  Yasmin Gosiengfiao, MD
AREN03B2 Renal Tumors Classification, Biology and Banking Study Yasmin Gosiengfiao, MD
AREN0532  Treatment of Very Low, Low and Standard Risk Favorable Histology Wilms Tumor  Yasmin Gosiengfiao, MD
AREN0533 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors   Yasmin Gosiengfiao, MD
AREN0534 Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor Yasmin Gosiengfiao, MD
     
  Retinoblastoma (RET):   Investigator 

ARET0321

 A Trial of Intensive Milti-Modality Therapy for Extra-Ocular Retinoblastoma Joanna Weinstein, MD
 AEPI05N1  Carcinogen Metabolism, DNA Repair, Parental Exposures and Retinoblastom  Joanna Weinstein, MD 
     
  Rhabdomyosarcoma (RST):   Investigator 
ARST0332  Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas NRSTS   David Walterhouse, MD
ARST0531 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma   David Walterhouse, MD
ARST08P1 A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma  David Walterhouse, MD
ARST0921  A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma  David Walterthouse, MD
D9902  A Group-Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens. An Intergroup Rhabdomyosarcoma Study Group Protocol David Walterhouse, MD
ONC 0905 A Pediatric Study of Vincristine Pharmacokinetics and Pharmacogenetics in Rhabdomyosarcoma Patients David Walterhouse, MD